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It  is now well established that  in  mice the  immune  response  to  many  antigens, 
including hapten-protein conjugates, requires the participation of two distinct classes 
of lymphocytes, one derived from the thymus (T cells)  1 and the second from the bone 
marrow  (B  cells) (1-3). Both cell types recognize antigens; T  cells appear to be  in- 
volved in  cell-mediated immune  reactions while  the  antibody response  to  a  large 
number of antigens, including hapten-protein conjugates, involves the cooperation of 
both T  and B cells. In the latter case, T  cells have been shown to recognize the carrier 
while B cells manufacture antibody to the haptenic determinant (4). The ability of the 
cells to recognize antigens is explained by the "receptor hypothesis," which states that 
the  lymphocytes  have  on  their  surface  immunoglobulin-like molecules  which  are 
specific for antigens (5). The interaction of the membrane receptor with its specific 
antigen  induces  cell proliferation resulting  in  specific cellular and/or  humoral  im- 
munity.  There  now  exists  a  considerable amount  of  experimental evidence which 
supports the receptor hypothesis (6). 
When  lymphocytes  from  animals  immunized  with  haptens  coupled  to  foreign 
carriers are cultured in vitro, addition of the hapten-carrier complex or the carrier by 
itself induces specific cell proliferation which can be measured by the  increased in- 
corporation of tritiated thymidine ([SH]T) into the DNA of dividing cells. This pro- 
liferation precedes the development of antibody-forming cells (B cells) and is thought 
to be due primarily to T  cell stimulation (7). Less is known about the participation 
of T  and B  cells in responses to  haptens on isologous carriers. We have previously 
shown  that  spleen cells from  mice immunized with  the  hapten 4-hydroxy-3-iodo-5- 
nitrophenylacetic acid  (NIP)  coupled  to  a  nonimmunogenic  isologous carrier,  i.e. 
mouse  gamma  globulin  (MGG),  will respond  in  vitro  specifically to  that  antigen 
* Supported in part by grants AM10145 and AI-TI00013  from the United States Public 
Health Service. 
1  Abbreviations used in this paper: B cell, bone marrow-derived  cell; BSA, bovine  serum 
albumin; BSS, balanced salt solution;  CFA, complete Freund's adjuvant; DNP, 2,4-dinitro- 
phenyl; EACA,  epsilon-aminocaproic  acid; FDNB, p-fluorodinitrobenzene;  [3H]T, tritiated 
thymidine; MGG, mouse gamma globulin;  NIP, 4-hydroxy-3-iodo-5-nitrophenylacetic  acid; 
OA, ovalbumin; PBS, phosphate-buffered  saline; PHA, phytohemagglutinin; T cell, thymus- 
derived cell; TCM, tissue culture medium, 
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(NIP-MGG) with increased DNA synthesis  (8). The carrier alone does not stimulate 
the cells. 
The  present  report  describes  experiments  in  which  the  participation  of  T 
and B  cells in  the total in vitro response  was  studied.  Specific removal of T  or 
B  cells was  accomplished  by  treating  the  lymphocytes  with  complement  plus 
antiserum  specific for surface  antigens  (theta),  immunoglobulins  (IgM),  both 
heavy-  and  light-chain  components  (polyvalent  antiserum),  and  by  passage 
through  anti-MGG-coated  columns.  The  results  demonstrate  the  following 
points:  (a)  the  in  vitro  response  is  highly  dependent  on  T  cells;  (b)  a  large 
portion of the in vitro response,  as much as 40-50 %,  is contributed  by B  cells; 
(c)  the  responding  B  cells  carry  immunoglobulin  determinants  of  IgM  mole- 
cules; (d)  responding T  cells may have specificity directed to the  hapten as well 
as  to  the hapten-protein  complex. 
Materials and Methods 
Animals.  Adult inbred BALB/c mice were obtained from the American Medical Center, 
Denver, Colo. 
Antisera.-  AKR anti-C3H 0 serum was prepared  as previously described  (9). Antiserum 
against  mouse  IgM was  obtained  from  Meloy Laboratories,  Inc.,  Falls  Church,  Va.  "fhe 
antisera were raised  in goats to purified IgM ()~) obtained from mice bearing myeloma tumor 
MOPC  104E.  During  immunoelectrophoresis,  the  antiserum  forms  a  single  precipitin  line 
corresponding to IgM when tested against whole mouse serum. Antisera against  MGG were 
prepared  by immunizing rabbits  with heat-killed Salmondla  adelaide bacteria  coated  with 
mouse anti-Salmondla  adelaide antibodies.  These antisera  have antibodies directed  against 
both heavy- and fight-chain determinants of all mouse immunoglobulins. Before use, all sera 
were inactivated at 56°C for 30 min and absorbed with 1 ml of packed BALB/c erythrocytes 
(1  ml packed  erythrocytes/5 ml antiserum).  In addition,  rabbit  anti-MGG serum and  goat 
anti-IgM serum were absorbed twice at 1/20 vol/vol with packed BALB/c thymocytes. 
Antigen.  MGG was  prepared  and  purified  as  previously described  (8).  Bovine  serum 
albumin (BSA, fraction V) was purchased from Pentex Biochemical, Kankakee, Ill. The hal> 
tens used were NIP and 2,4-dinitrophenyl group  (DNP). NIP-protein coupling was carried 
out according to the method of Brownstone et al. (10) and yielded a ratio of 8  10 NiP/mole- 
cule of NIP-MGG. DNP-BSA coupling was accomplished by the method of Little and Eisen 
(11) and yielded an approximate ratio of 4-5 DNP/molecule of DNP-BSA. 
Immunization.--BALB/c mice were immunized intraperitoneally with 400 beg NIP-MGG 
in complete Freund's adjuvant  (CFA) (Difco Laboratories, Detroit, Mich.). 
Skin Painting.  BALB/c mice were sensitized to p-fluorodinitrobenzene (FDNB) accord- 
ing to the method of Taylor and Iverson (12). The mice were painted once a week for 4 or 5 
wk and  sacrificed  for preparation  of lymph node cell suspensions  within  7 days of the last 
painting. 
Cell Preparation  and  Culture.--Single-cell  suspensions  of  spleen  cells  from  NIP-MGG 
(CFA)-immunized mice and  lymph nodes  (popliteal,  inguinal,  axillary,  and  cervical) from 
FDNB-sensitized  mice  were  prepared  and  cultured  as  previously  described  (8).  Briefly, 
4 X  106 spleen or lymph node cells were cultured with and without antigen in disposable glass 
culture  tubes  (16  X  100  mm)  with  Morton  closures  in  1 ml RPMI-1640  medium  (Grand 
Island Biological Co., Grand Island, N. Y.) containing 5% heat-inactivated rat serum, 100 U 
penicillin G, and  100 beg streptomycin/mI  (complete tissue culture medium, TCM).  On the 
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was pulsed for 5 h with 1 #Ci of [3H]l" (6 Ci/mmol, Schwarz/Mann Div., Becton,  Dickinson 
& Co., Orangeburg, N. Y.).  DNA synthesis was determined by precipitating TCA-insoluble 
material on glass fiber filters (H. Reeve Angel & Co., Inc., Clifton, N. J.) and by counting in 
a Packard Tri-Carb liquid scintillation spectrometer (Packard Instrument Co., Inc., Downers 
Grove, Ill.). 
Activation of Thymus Cells by N[P-MGG.--IO0  X  106 BALB/c thymus cells were injected 
intravenously on two successive days  (200  X  106 total cells) into BALB/c recipients which 
had received 750 R  6°Co irradiation. 4-6 h after the second intravenous injection, each mouse 
received 400 ~g of NIP-MGG  (CFA) or CFA only intraperitoneally. 8 days later, the mice 
were sacrificed and the spleen cells cultured. 
Treatment of Cell Cultures with Antisera.--Spleen  or lymph node cells were suspended in 
RPMI-1640 medium without serum at 5 X  106 cells/ml. 0.8 ml (4 X  106 cells) was added to 
each culture tube together with 0.1  ml of dilutions of antisera or normal sera and 0.1  ml of 
fresh guinea pig serum  (diluted  1:3)  previously absorbed with agarose  (13).  After 45 min 
incubation at 37°C, 5 ml of cold Earle's balanced salt solution (BSS) was added to each tube, 
the tubes centrifuged for 5 min, and the supernatant discarded.  The cell pellets were then 
gently resuspended in  1 ml of TCM and cultured for 3  days with and without antigen or 
phytohemagglutinin (PHA)  (Difco). 
In Vitro Blocking of Hapten-Specific Stimulation.--In  blocking experiments, 4 X  106 spleen 
cells suspended in  TCM  were  incubated for 3  h  at  37°C  with different concentrations of 
NIP-epsilon-aminocaproic acid  (NIP-EACA)  prepared according to  the method of Brown- 
stone et al.  (10).  At the end of 3  h, antigen or PHA was added,  the NIP-EACA was not 
removed, and the cells were cultured for 3 days as described. 
Preparation of Rabbit Anti-MGG-Coated Column.--The  method used was essentially that 
of Golstein et al.  (14).  Briefly, polymetaacrylic plastic particles with an average diameter of 
250 #m (Degalan V26, Degussa Wolfgang AG., Hanau am Main, W. Germany) were washed 
several times with sterile distilled water followed  by  two  washes  with sterile  phosphate- 
buffered saline (PBS), pH  7.4.  The beads were then mixed with ammonium sulfate-precipi- 
tated pooled MGG (2 mg/ml in PBS) and incubated at 45°C for 1 h. After overnight incuba- 
tion at 4°C, the beads were poured into each of two 30-ml syringes and washed with 100 ml of 
sterile saline. Each syringe was then filled with either normal rabbit serum or rabbit anti- 
MGG serum diluted 1 : 5 in saline and incubated at 4°C for 2 h. Each column was then washed 
with 70 ml of Earle's BSS containing penicillin and streptomycin and 30 ml of RPMI-1640 
medium with antibiotics. After this washing, 2-3 ml (400 X  106-600 X  106 cells) of the spleen 
cell suspension were added to each column and eluted with RPMI-1640 medium at a  rate of 
2-3 ml/min. Approximately 21% of the cells were recovered from the normal rabbit serum- 
coated column and 14% from the anti-MGG-coated column. The eluted cells were then washed 
once and cultured as described. 
RESULTS 
We  have  previously  demonstrated  that  mice  immunized  with  NIP-MGG 
(CFA)  produce  NIP-specific  plaque-forming  ceils  and  the  spleen  cells  from 
these mice respond  to  the antigen in vitro with increased  DNA  synthesis  (8). 
To  investigate the participation of T  and B  cells in the total in vitro response 
to  the  hapten-protein  conjugate,  spleen  cells from  immunized  mice  were  pre- 
treated in vitro in ways to selectively remove T  or B  cells. After treatment,  the 
cells  were  washed  and  cultured  for  3  days  with  or  without  antigen.  The  in- 
corporation of [3H]T into the DNA  of the antigen-stimulated cells was used  to 
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pensions,  separate cultures were stimulated with PHA. Previous studies have 
shown  that  the  lymphocytes which  respond  to  PHA  in  vitro  are  thymus 
derived (15). 
Inhibition  of the In  Vitro  Response  of Spleen Cells to NIP-MGG by A nti-O, 
Anti-IgM,  or  Anti-MGG  Sera.--Table  I  shows  the  results  obtained  from 
treating spleen cell cultures from immunized mice with three separate antisera 
TABLE  I 
Inhibition of In Vitro NIP-MGG and PHA Responses of Primed Mouse Spleen  Cells 
by Pretreatment with Anti-O, A nti-lgM, or Polyvalent  A nti-MGG Antiserum 
and Complement 
Treatment  of cells  Final  serum 
in vitro  dilution 
Stimulant  added 
Percent 
inhibition 
of response* 
NIP-MGG  NIP-  PI]A  None  (500 #g/ml)  PHA  MGG 
cpm (range)  cpm  (range)  cpm (range) 
NMS~ -l-  C§  (1:20)  851  8,151  18,894 
(564-1,019)  (3,988-18,753)  : 13,257-26,921  ) 
Anti-0 3c  C  (1:20)  578  2,228  3,686  77.4  82.8 
(325-969)  ~  1,358-3,233)  (783-9,872) 
NGSII q- C  (1:40)  1,562  9,940  25,035 
(1,070-2.439)  (5,269-17,477 )  (9.997-47,190) 
Anti-IgM +  C  (1:40)  772  5,263  27,265  46.4  0 
(6~6-934)  i3,036-8,513)  (15,093-44.274) 
NRS¶ +  C  (1:40)  723  6,886  ND** 
(521-1,058)  (2,544-13,299) 
Anti-MGG:~; +  C  (1:40)  1,146  4,287  ND  49.0 
(1,038  1,231)  (1,946-7,280) 
BALB/c mice were immunized with 400 /~g NIP-MGG (CFA)  i.I~. 2  4 wk later, spleen cell suspensions were 
prepared, treated with different antisera plus complement (C), and cultured for 3 days with or without NIP-M GG 
or PItA. Results are expressed as the mean of four separate experiments together with experimental ranges. 
* Calculated  as described ill  Results. 
Normal AKR mouse serum. 
§ Fresh guinea pig serum, final dilution  1:30. 
I Normal goat serum. 
¶  Normal rabbit  serum. 
** Not done. 
;+~ Polyvalent  antiserum. 
plus  complement. The  results  are  expressed  as  the  mean of four separate  ex- 
periments together with the experimental ranges. The percent inhibition of the 
response was calculated according to the following equation: 
100  --  [(Antiserum-treated) cpm stimulated  -- cpm unstimulated]  X  100. 
[(Normal serum-treated) cpm stimulated  -- cpm unstimulated] 
Treatment  of  the  spleen  cells  with  anti-0  complement  resulted  in  a  77%, 
inhibition of the NIP-MGG response. The same treatment of replicate cultures 
inhibited the PHA response by 83 % showing that a very large portion of the T 
cells were killed  by the antiserum. 
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forming cell precursors (B cells) is now a  well established fact. Both IgG and 
IgM and the heavy chains of these molecules have been demonstrated on the 
surface of these lymphocytes (6,  16-19).  To determine the participation of B 
cells in  the in vitro response to NIP-MGG, spleen cells were pretreated with 
purified antimouse IgM antiserum plus complement (Table I). The anti-IgM 
treatment resulted in a 46 % inhibition of the NIP-MGG response. Absorption 
of the antiserum with purified IgM completely removed its inhibitory activity. 
Of more significance was the finding that the same anti-IgM treatment had no 
effect on the PHA response of the spleen cells. We have interpreted these results 
as strong evidence that the anti-IgM was killing only B cells, some of which were 
responding to the NIP-MGG in vitro. Similar results were obtained by treating 
the spleen cells with polyvalent anti-MGG serum. This treatment reduced the 
NIP-MGG response by 49%. Although the cell type, i.e. B cell or T  cell, that is 
being affected by the polyvalent anti-MGG cannot be determined from these 
results, the similarity between the inhibition produced by the  anti-MGG  and 
that produced by pretreatment with anti-IgM suggests that the effect is pri- 
marily at the B cell level. 
Inhibition  by Anti-6 or Anti-IgM Serum of the Response of Lymphocytes from 
Mice Skin Painted with FDNB.--Painting the skin of mice with highly reactive 
compounds such as FDNB has been shown to be an effective way of inducing 
delayed hypersensitivity, primarily a  T  cell-mediated immune reaction.  Mice 
sensitized in this way form little if any antibody specific for DNP which shows 
it is a very poor method for inducing humoral antibody, i.e., activating B cells. 
We have tested, by hemagglutination (20), the sera from 12 skin-painted mice 
used in these studies  for the presence of anti-DNP  antibodies,  but none was 
found. Based on these findings, FDNB sensitization provided us with an addi- 
tional  hapten-specific in  vitro  response,  mediated primarily if not  totally by 
T  cells,  on which  we could  test  the  specificity of the  different  antisera  with 
respect  to  the  cell  populations  that  were  being  killed.  Lymph  nodes  from 
skin-painted mice were removed and single-cell suspensions cultured  as previ- 
ously described.  DNP-BSA  was found  to be the  best  stimulating  antigen  in 
vitro while BSA by itself did not stimulate the lymph node cells. 
Table II shows the results obtained from treating the lymph node cells with 
anti-0  or  anti-IgM  serum plus  complement.  The  results  are  presented  as  in 
Table I  and represent the mean of three to four experiments. 
Treatment  of  the  lymph  node  cells  with  anti-~  inhibited  the  DNP-BSA 
response by 66 %. These results agree favorably with those obtained by treating 
spleen  cells  from NIP-MGG-immunized mice  with  anti-~  serum.  More  im- 
portant  in  this  series  of  experiments was  the  finding  that  treatment  of  the 
lymph  node  cells  with  anti-IgM  had  no  inhibitory  effect on  the  DNP-BSA 
response. These results together with  the PHA stimulation shown in Table I 
are even stronger evidence that the anti-IgM serum is not killing T  cells and 
that the inhibition of the NIP-MGG response by anti-IgM treatment is due to 
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"FABLE II 
Effect of Pretreatment by Anli-O  or Anti-lgM  Antiserum  Plus Complement on  the In  Vitro 
DNP-BSA  Response of Lymph Node Calls  from Mice Sensitized 
to p-Flurodinitrobenzene 
Treatment  of cells in vitro 
Stimulated  added 
None  DNP-BSA  (100 gg/ml) 
Percent  inhibition 
of response* 
epm (range)  cpm  (range) 
NMS{ +  C§  380  1,087 
(315 444)  (1,032-1,142) 
Anti-0 +  C  241  480 
(128-355)  (307-653) 
NGSI[ +  C  551  2,318 
(368 879 )  (1,060-3,957 ) 
Anti-IgM +  C  551  2,484 
(342-812)  (994-3,896) 
66.2 
BALB/c mice were skin-painted once a week for 4  5 wk. Within 7 days of the last painting 
lymph node cell suspensions were prepared, treated with different antisera plus complement, 
and cultured for 3 days with or without DNP-BSA. The results are expressed as the mean of 
three to four experiments  together with experimental ranges. 
* Calculated as described in Results. 
{ Normal AKR mouse serum. 
§ Fresh guinea pig serum, final dilution 1:30. 
]I Normal goat serum. 
Inhibition of the In  Vitro XIJP-MGG Response by Filtration of Immune Spleen 
Cells through a Column Coated with A nti-MGG A ntiserum.--Golstein et al. have 
recently reported that passage of immune spleen cells through a  column coated 
with anti-MGG antiserum results in the specific and ahnost complete retention 
of  B  cells on  the  column  (14).  T  cells, on  the  other hand,  pass  through  the 
column freely. As another means of investigating the participation of hapten- 
specific B  cells in  the in vitro NIP-MGG  response, immune  spleen cells were 
passed  through  anti-MGG-coated  columns.  After  passage,  the  ceils  were 
washed and cultured with and without antigen or PHA. The filtered cells were 
also tested for NIP-specific plaque-forming ceils (21)  and rosette-forming cells 
(22)  to determine the extent of B  cell depletion. 
The combined results of three separate experiments are shown in Table IfI. 
Passage of the spleen cells through  the anti-MGG columns  resulted in a  48 % 
inhibition of the NIP-MGG  response. These same cells had an average of 78% 
fewer  NIP-specific plaque-forming cells and  86%  fewer NIP-specific rosette- 
forming cells (data not shown), which demonstrates that the column filtration 
caused extensive B  cell depletion. On the other hand,  the ability of the filtered 
cells  to  respond  to  PHA  was  unimpaired,  demonstrating  that  the  colunm 
filtration had not selectively depleted the spleen cell suspension of T  cells. These 
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TABLE III 
Immune Spleen  Cell Responses  to NIP-MGG and PHA after Passage  of the Cells tllrough Bead 
Columns  Coated with Rabbit Polyvalent  Anti-MGG Serum or Normal Rabbit  Serum 
Stimulant added  Percent inhitition 
Column coated with  of response* 
None  NIP-MGG (500 ~g/ml)  PHA  NIP-MGG PHA 
cpm  cpm  cpm 
NRS ~:  863  10,867  70,594 
(353-1,505)  (4,788  17,105)  (49,345-86,266) 
Anti-MGG§  566  5,707  71,559 
(460-752)  (3,958-7,492)  (61,767-78,952) 
47.5  0 
BALB/c mice were immunized with 400/zg NIP-MGG (CFA) i.p. 2-4 wk later, spleen cell 
suspensions were prepared and passed through bead columns coated with either polyvalent 
anti-MGG serum or NRS. The cells which passed through the column were cultured for 3 
days with NIP-MGG or PHA. The results are expressed as the mean of three separate ex- 
periments together with experimental ranges. 
* Calculated as described in Results. 
Normal rabbit serum. 
§ Polyvalent antiserum. 
NIP-MGG response after anti-IgM and anti-MGG treatment was the result of 
B cell inactivation. 
Activation  of Thymus Cells by NIP-MGG.--In  a previous report, we demon- 
strated that nearly 50 % of the in vitro response of primed spleen cells to NIP- 
MGG  could  be  blocked by NIP-EACA and that  the  inhibition  was  hapten 
specific  (8).  In experimental systems utilizing haptens coupled to heterologous 
protein carriers where both the hapten-protein complex and the carrier alone 
can stimulate cells in vitro, such blocking would generally be thought to occur 
via  B  cells  since B  cells  have hapten  specificity whereas T  cells  have carrier 
specificity. However, with NIP-MGG, the carrier is an isologous protein  and 
cannot stimulate the spleen cells by itself.  Therefore, using NIP-MGG, it was 
of interest to determine what part the hapten was playing in stimulating T cells 
to proliferate in vitro. To achieve this with a  "relatively pure" T  cell popula- 
tion, thymus cells were activated by NIP-MGG (see Materials and Methods), 
and the effect of NIP-EACA on the antigen-induced proliferative response was 
determined. Representative results of such experiments are shown in Table IV. 
Spleen cells  from irradiated  BALB/c mice receiving thymus cells  and CFA 
only did not respond in vitro to either NIP-MGG or MGG (group A). How- 
ever,  the spleens from these mice did  contain functional T  cells  as shown by 
their  ability  to  respond  to PHA.  In  contrast  to  this,  spleen  cells  from mice 
receiving thymus cells and NIP-MGG (CFA) responded very well to NIP-MGG 
in vitro although they were unable to respond to MGG by itself (group B). The 
importance  of  the  hapten  for  T  cell  stimulation  was  demonstrated  by  the 
blocking effect of NIP-EACA. The response to NIP-MGG was inhibited in  a 418  IMMUNOLOGIC  REACTIONS  TO  IIAPTENS.  i 
TABLE  IV 
in  Vitro Response of T Cells Activated by NIP-MGG; Requirement [or and Response 
lo the Hapten NIP 
~  ~  Thymus cell  recipients  ~  ~  Treatment  in vitro  Stimulant  added  cpm ±  SE  %  Inhi-  ~  c  injected  with  bition* 
~.l'"  ¢3 
b~g/ml  #g/~z  l 
1  A  CFA+..  None  None  1,308  -4-  25 
CFA  None  NIP-MGG (500)  1,187  ±  60 
CFA  None  MGG (500)  1,161  4.  31 
CFA  None  PHA  10,914  ±  389 
B  NIP-MGG (CFA)  None  None  1,500  4-  247 
NIP-MGG (CFA)  None  NIP-MGG (500)  5,327  -4-  363 
NIP-MGG (CFA)  None  MGG (500)  1,535  4.  303 
NIP-MGG (CFA)  NIP-EACA (50)  NIP-MGG (500)  4,629  4-  1,059  16.5 
NIP-MGG (CFA)  NIP-EACA (100)  NIP-MGG (500)  3,579  :t: 111  41.4 
2  NIP-MGG (CFA)  None  None  754  =k:  18 
NIP-MGG (CFA)  NMS§ q- C  NIP-MGG (500)  3,568  4. 253 
NIP MGG (CFA)  Anti-0  -1-  C  NIP-MGG (500)  663  4-  118  100 
Lethally  irradiated BALB/c mice  received 200 X  l0  t  syngeneic  thymus  cells  i.v.  together  with 400/zg NIP- 
MGG (CFA) or CFA only  i.p. 8 days later spleen  cell  suspensions  were prepared and cultured  for 3 days with 
or without antigen  or PHA, Blocking  of the response was accomplished  by incubating  the cultures  for 3 h with 
N[P-EACA before NIP-MGG was added for the remainder  of the 3 days. Results  are expressed as the mean of 
triplicate  cultures  4- standard error, 
* Calculated  as described  in Results, 
{ Complete  Freund's  adjuvant. 
§ Normal AKR mouse  serum. 
dose-dependent  way by the NIP-EACA with a  maximum inhibition  of 41%. 
Finally,  to  insure  that  the  response  we  were  detecting  was  in  fact  T  cell, 
activated spleen cells were treated with anti-0 serum plus complement. As shown 
in  experiment 2,  Table  IV, such  treatment completely abolished  the response 
to NIP-MGG. 
DISCUSSION 
The present report investigates the participation of both T  and B cells in the 
in  vitro  response of spleen  cells  from mice immunized with  the  hapten  NIP 
coupled  to  a  nonimmunogenic  isologous  gamma  globulin  carrier  (MGG). 
Previously,  the  use  of defined  haptens  coupled  to  heterologous  carriers  has 
yielded valuable information regarding the interaction of antigen and ceils (3). 
The production of antihapten antibodies depends on cooperation between T and 
B cells. Furthermore, the in vivo experiments of Mitchison (4) together with the 
recent in vitro experiment of Cheers et al. (23) clearly demonstrate that  in  the 
cooperative system T cells recognize the foreign carrier and B cells recognize the 
haptenic group and manufacture antihapten antibodies. 
The use of haptens coupled to nonimnmnogenic isologous carriers for induc- 
tion of specific immunity or tolerance is relatively new and consequently less is 
known  about  cell  interactions  and  about  how  the  molecule  is  recognized  as 
foreign.  The present  results clearly denmnstrate  that  both T  and  B  cells  are 
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The participation of T  cells was demonstrated in two ways. First,  treatment 
with  anti-0 serum  resulted in  a  77 %  inhibition of the secondary in vitro  re- 
sponse to NIP-MGG. That this inhibition was due to removal of T  cells was 
shown by the 83 % inhibition by anti-0 of the PHA response of replicate cultures. 
Furthermore,  the  activation  experiments  clearly  demonstrated  that  a  rela- 
tively pure population of adoptively transferred and stimulated  thymus cells 
could be specifically restimulated by NIP-MGG in vitro and that this response 
was sensitive to anti-0 treatment. However, the demonstration that removing 
T  cells almost  completely abrogates  the  response does not necessarily mean 
~hat only T  cells are responding. In hapten-protein stimulation, as is the case 
with many other antigens, antigen-induced proliferation of B cells requires the 
helper effect of T  cells; i.e., B cells cannot be made to proliferate by interaction 
with  antigen  alone.  Thus,  killing  of antigen-specific T  cells  would  not  only 
eliminate the bulk of the T  cell response, but would also indirectly by removal 
of helper cells, inhibit hapten-specific B cell proliferation. The inhibition of the 
NIP-MGG response by anti-0 treatment thelefore shows that the total in vitro 
response depends on T cells, but it does not necessarily mean that all of the cells 
responding to the antigen are themselves T  cells. 
The participation of B cells in the secondary response was also investigated. 
There  now  exists  substantial  evidence  to  support  the  receptor  hypothesis 
demonstrating the existence of immunoglobulin determinants on the surface of 
lymphocytes. Determinants  of both #  and "),-type  have been clearly demon- 
strated on the surface of B cells by immunoflurorescence, autoradiography, and 
cytotoxicity using anti-# or anti-3' serum plus complement (16-19, 24).  In this 
report, we tested the active participation of B  cells in the secondary in vitro 
response  to  NIP-MGG  by  stimulating  primed  ceils  before  and  after  pro- 
cedures  designed  to  remove  B  ceils  selectively. These procedures  were  (a) 
passage of spleen cells through a  column coated with anti-MGG, a  technique 
which has been previously shown to specifically remove B  cells (14),  and  (b) 
treatment of primed spleen cells with anti-IgM or anti-MGG serum plus com- 
plement.  Anti-MGG  column  treatment  of  NIP-MGG-primed  spleen  cells 
caused  a  significant reduction in  the number of NIP-specific plaque-forming 
cells and NIP-specific rosette-forming cells,  both of which are functions of B 
cells.  Furthermore,  the  in  vitro proliferative response  to  NIP-MGG  of  the 
passed cells was inhibited 47 % while their ability to respond to PHA was not 
affected. Treatment of primed spleen cells with anti-IgM or anti-MGG serum 
plus complement also caused a significant inhibition of the in vitro NIP-MGG 
response (46 and 49% respectively), but had no effect on the PHA response of 
the same cells. These results, showing that procedures which selectively deplete 
populations of B  cells entail a  40-50% reduction in the secondary response to 
NIP-MGG, clearly indicate that B cells contribute to the response. 
In such experiments, it is crucial to establish the specificity of reagents de- 
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were  eliminated  by our  anti-IgM  antiserum  was  shown  in  two  ways.  First, 
PHA responses were not diminished after anti-IgM treatment. Secondly, anti- 
IgM treatment of lymph node cells from FDNB-sensitized mice had no effect 
on the ability of these ceils to respond to DNP-BSA in vitro, a  response which 
seems to be mediated totally by T  cells.  Some investigators, however, have re- 
ported the existence of/~-chains on "immune" T  cells (25). Our results do not 
substantiate  these  findings.  This  discrepancy is  characteristic  of  the  current 
controversy  about  the  nature  of  T  cell  receptors  (26).  With  regard  to  this 
controversy, it should be noted that in our investigation of T  cell participation, 
the onh, anti-T cell  reagent we used was anti-0 serum; there seems to be little 
doubt regarding its specificity for T  cells (27). 
The results  reported  in  this paper also have implications for tolerance  e.~- 
periments. The induction of hapten-specific tolerance using DNP coupled to an 
isologous carrier has been recently reported by Golan  and Borel  (28).  In our 
first  report  (8),  we  also  demonstrated  that  hapten-specific tolerance  to  NIP 
could be induced  in mice challenged with NIP-MGG (CFA)  by pretreatment 
with  soluble  NIP-MGG. With  respect  to  current  immunological views,  this 
hapten-specific  tolerance  results  from  B  cell  inactivation.  However,  spleen 
cells from those  tolerant  mice were  also unable  to  respond  to NIP-MGG in 
vitro. The results presented in this paper dearly show that T  cells respond to 
NIP-MGG  in  vitro.  Therefore,  it  is  clear  that  pretreatment  of  mice  with 
soluble NIP-MGG results not only in B cell tolerance to NIP but also in T  cell 
tolerance to NIP-MGG. 
Finally, the results from the thymus cell activation experiments reported here 
deserve some special comment because, we believe, they suggest the existence 
of hapten-specific T  cells. Mitchison (29), Iverson (30), and Taylor and Iverson 
(12) have all reported the existence of hapten-specific helper cells using FDNB- 
sensitized mice. However, the interpretation of these results as clearly showing 
helper cell activity mediated via the haptenic DNP group has recently become 
unclear by the demonstration of Janeway that a similar effect can be produced 
by transfusion of serum containing  anti-DNP  antibodies  (31).  In our system, 
thymus  ceils  could  be  specifically activated  by NIP-MGG and  the  cells  re- 
sponded very well in vitro to the hapten-carrier complex but not to the carrier 
alone.  Furthermore, 41%  of the response could be blocked by the addition  of 
100/~g  NIP-EACA. The inability- of the carrier (MGG) alone to  stimulate  the 
cells demonstrates the absolute necessity of the hapten for antigen recognition 
by  the  T  cells.  (In  a  similar  system  using  NIP-ovalbumin  [OA]-activated 
thymus cells,  OA by itself stimulates the cells nearly as well as does NIP-OA, 
demonstrating  that  the hapten is not required for this in vitro response to a 
heterologous carrier.) We believe that with NIP-MGG the antigen recognition 
involves cell receptors directed in part to the hapten and in part to the carrier. 
Blocking  of  the  response  would  therefore  be  the  result  of  steric  hindrance 
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60%  of the response is not  blocked by NIP-EACA allows for an  alternative 
explanation. 
It is possible that the activation of T  cells to NIP-MGG results in the expan- 
sion of two separate clones of cells.  One clone clearly has specificity for NIP- 
MGG while a second clone may have specificity for NIP only. The receptors on 
the  cells specific for NIP-MGG would  be expected to  have relatively higher 
affinity for the conlplex and lower affinity for NIP alone. The hapten-specific 
cells would have "receptors" with higher affinity for the hapten alone and lower 
affinity for the complex. Addition of NIP-MGG would result in stimulation of 
both  cell clones. However, NIP-EACA would  bind preferentially to  the  cells 
with NIP specificity, thus preventing them from responding to NIP-MGG. 
Definitive results supporting this latter interpretation are not yet available. 
However, it seems clear that profound differences may exist with respect to T 
cell  recognition  of haptens  depending  primarily on  whether  the  carrier is  an 
isologous or heterologous protein. We believe that the use of haptens coupled 
to  isologous  carriers  opens  new  areas  and  approaches for  the  stud)"  of both 
immunity and tolerance directed to a defined antigenic group. 
SUMMARY 
Both  thymus-derived  (T)  and  bone  marrow-derived  (B)  lymphocytes 
participate  in  the  response  to  a  hapten 4-hydroxy-3-iodo-5-nitrophenylacetic 
acid  (NIP),  coupled  to  a  nonimmunogenic  isologous  carrier,  mouse  gamma 
globulin  (MGG). Spleen cells from mice immunized with NIP-MGG show in- 
creased DNA synthesis in vitro when cultured with NIP-MGG. The participa- 
tion of and requirement for T  cells in the response was demonstrated by treat- 
ing the spleen cells with anti-0 serum. This treatment resulted in a 77 ~. inhibi- 
tion  of  the  antigen  response.  Furthermore,  adoptively  transferred  normal 
thymus cells could be specifically "activated" by NIP-MGG in vivo and they 
responded secondarily to the antigen in vitro. 
The  active participation  of B  cells  in  the  secondary response was  demon- 
strated by passing the immune spleen cells through a column coated with poly- 
valent anti-MGG serum. Column filtration reduced the number of NIP-specific 
plaque-forming cells and NIP-specific rosette-forming cells  (both functions of 
B cells) and produced a 47 % inhibition of the NIP-MGG response. The ability 
of  the  cells  to  respond  to  phytohemagglutinin  (PHA)  was  not  affected  by 
column  filtration  showing  that  T  cells  were  not  being  selectively removed. 
The participation of B cells in the in vitro NIP-MGG response was also shown 
by treatment of the spleen cells with  antiserum specific for MGG and MGG 
determinants. B cells were removed by treatment with anti-IgM or polyvalent 
anti-MGG serum plus complement, resulting in a respective 46 and 49 % inhi- 
bition of the response to NIP-MGG. (Treatment with anti-IgM serum had no 
effect on T  cells.) 
The contribution  of the  hapten  NIP  to stimulation  of T  cells  was  investi- 422  IMMUNOLOGIC  REACTIONS  TO  IIAPTENS.  I 
gated  using  NIP-MGG-activated  thynms  cells.  These  activated  T  cells  re- 
sponded  in  vitro  very well  to  the  NIP-MGG  complex but  not  to  the  MGG 
carrier alone demonstrating the requirement of the hapten  for T  cell stimula- 
tion. The  response was  also partially inhibited  (41~{:)  by incubating the acti- 
vated  cells  with  NIP  coupled  to  a  single  amino  acid  (epsilon-aminocaproic 
acid)  before  addition of NIP-MGG.  These  results  demonstrated  that  T  cells 
recognize the hapten NIP when it is coupled to the isologous carrier MGG. 
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